ArticleMicrobiology (Reading, England)2010
Candida albicans forms biofilms on the vaginal mucosa.
Article in Microbiology (Reading, England), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 145 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
145 citing papers in PubMed, 297 citations in OpenAlex.
- Phenotypic and genotypic analysis ofInfection and immunity · 2026Article
- Escalating Antifungal Resistance AmongPathogens (Basel, Switzerland) · 2026Article
- Devising a Zfu2p targeted antifungal strategy that may preserve commensalism while suppressing Candida albicans virulence during vulvovaginal candidiasis.Scientific reports · 2026Article
- Dissolving Microneedles Loaded with Lipid Nanocarriers for Vaginal Delivery of Clotrimazole:Molecular pharmaceutics · 2026Article
- Experimental biofilm models for pharmacokinetic and pharmacodynamic investigations: bridging in vitro, ex vivo and in vivo systems.The Journal of antimicrobial chemotherapy · 2026Review
- Fluconazole-Resistant and Virulence-Associated Yeasts from the Vulva: Evidence of a Potential Reservoir.Journal of fungi (Basel, Switzerland) · 2026Article
- Reversibly Cross-Linked Asymmetric Hybrid Open-Polysilsesquioxane Films Enhancing Clotrimazole Bioavailability and Anti-ACS applied materials & interfaces · 2025Article
- Article
- Yeast-derived glycolipids disrupt Candida biofilm and inhibit expression of genes in cell adhesion.Scientific reports · 2025Article
- Exploring the female genital tract mycobiome in young South African women using metaproteomics.Microbiome · 2025Article
- [Low-intensity pulsed ultrasound combined with nystatin treatment synergistically inhibits vaginalNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2025Article
- Vaginal Candida albicans infections: host-pathogen-microbiome interactions.FEMS microbiology reviews · 2025Review
- SUMO-targeted Ubiquitin Ligases as crucial mediators of protein homeostasis in Candida glabrata.PLoS pathogens · 2024Article
- Synergistic anti-virulence efficacy of citral and carvacrol against mixed vaginitis causing Candida albicans and Gardnerella vaginalis: An in vitro and in vivo study.The Journal of antibiotics · 2024Article
- Molecular Determinants Involved in Candida albicans Biofilm Formation and Regulation.Molecular biotechnology · 2024Review
- Characterization of a Lactobacillus gasseri strain as a probiotic for female vaginitis.Scientific reports · 2024Article
- Impaired neutrophil extracellular trap-forming capacity contributes to susceptibility to chronic vaginitis in a mouse model of vulvovaginal candidiasis.Infection and immunity · 2024Article
- Article
- In vitro study to assess modulation ofBiofilm · 2023Article
- Limosilactobacillus reuteri 29A Cell-Free Supernatant Antibiofilm and Antagonistic Effects in Murine Model of Vulvovaginal Candidiasis.Probiotics and antimicrobial proteins · 2023Article
85 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Current understanding of resistance and susceptibility to vulvovaginal candidiasis challenges existing paradigms of host defence against fungal infection. While abiotic biofilm formation has a clearly established role during systemic Candida infections, it is not known whether C. albicans forms biofilms on the vaginal mucosa and the possible role of biofilms in disease. In vivo and ex vivo murine vaginitis models were employed to examine biofilm formation by scanning electron and confocal microscopy. C. albicans strains included 3153A (lab strain), DAY185 (parental control strain), and mutants defective in morphogenesis and/or biofilm formation in vitro (efg1/efg1 and bcr1/bcr1). Both 3153A and DAY815 formed biofilms on the vaginal mucosa in vivo and ex vivo as indicated by high fungal burden and microscopic analysis demonstrating typical biofilm architecture and presence of extracellular matrix (ECM) co-localized with the presence of fungi. In contrast, efg1/efg1 and bcr1/bcr1 mutant strains exhibited weak or no biofilm formation/ECM production in both models compared to wild-type strains and complemented mutants despite comparable colonization levels. These data show for the first time that C. albicans forms biofilms in vivo on vaginal epithelium, and that in vivo biotic biofilm formation requires regulators of biofilm formation (BCR1) and morphogenesis (EFG1).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.